Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Skeptical Take on Current Alzheimer’s Therapy: FDA’s Temple Says Problem Is Drugs, Not Endpoints

This article was originally published in RPM Report

Executive Summary

When it comes to Alzheimer’s Drug development, FDA’s Bob Temple firmly believes regulatory standards are not the problem. “You just need a drug that works.”

You may also be interested in...



A New Direction For Alzheimer’s R&D: FDA Outlines Early Disease Pathway

Alzheimer’s R&D has suffered multiple failures over the last decade, with no drug found to slow or halt the underlying progression of the disease. Industry’s focus is now on patients at the very earliest stages of the disease, and FDA is meeting sponsors halfway, with a draft guidance outlining approval requirements.

A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway

Alzheimer’s R&D has suffered multiple failures over the last decade, with no drug found to slow or halt the underlying progression of the disease. Industry’s focus is now on patients at the very earliest stages of Alzheimer’s in the hopes of finding an effective drug before too much damage is done. FDA is meeting sponsors halfway, with a draft guidance outlining approval requirements.

Invaluable Guidance: FDA’s Dean of Drug Reviews on “Enrichment Strategies”

FDA’s draft guidance on “Enrichment Strategies for Clinical Trials” fulfills an overdue goal from PDUFA IV. It also captures decades of wisdom from the agency’s senior drug review manager.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS081083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel